Tempus AI (NASDAQ:TEM) Price Target Raised to $92.00

Tempus AI (NASDAQ:TEM) had its price target lifted by Cantor Fitzgerald from $80.00 to $92.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other brokerages have also recently weighed in on TEM. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $56.00 to $76.00 in a research note on Tuesday, September 1st. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Robert W. Baird upped their price objective on shares of Tempus AI from $85.00 to $92.00 and gave the company an “outperform” rating in a research note on Tuesday. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Finally, Rothschild & Co Redburn began coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $79.37.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $70.43 on Tuesday. The company has a quick ratio of 3.16, a current ratio of 2.61 and a debt-to-equity ratio of 2.70. The stock has a market capitalization of $12.71 billion, a price-to-earnings ratio of -66.44 and a beta of 3.61. The stock’s fifty day simple moving average is $71.21 and its 200 day simple moving average is $57.20. Tempus AI has a 52-week low of $40.77 and a 52-week high of $89.09.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The company had revenue of $411.54 million for the quarter, compared to analyst estimates of $409.39 million. During the same period in the previous year, the firm earned ($0.46) earnings per share. Tempus AI’s revenue for the quarter was up 23.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Tempus AI will post -1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Andrew Polovin sold 2,951 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $221,325.00. Following the completion of the sale, the executive vice president owned 135,189 shares in the company, valued at $10,139,175. This represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan Bartolucci sold 7,062 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $529,650.00. Following the completion of the sale, the chief accounting officer directly owned 60,804 shares of the company’s stock, valued at approximately $4,560,300. This trade represents a 10.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,237,227 shares of company stock valued at $85,388,983. 24.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of the business. Guardian Partners Inc. increased its stake in Tempus AI by 8.3% in the 3rd quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock valued at $213,000 after buying an additional 200 shares during the period. Kestra Private Wealth Services LLC lifted its position in Tempus AI by 1.4% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 18,685 shares of the company’s stock worth $1,530,000 after buying an additional 257 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in Tempus AI in the 3rd quarter worth approximately $27,000. ProShare Advisors LLC lifted its position in Tempus AI by 5.9% in the 3rd quarter. ProShare Advisors LLC now owns 6,500 shares of the company’s stock worth $532,000 after buying an additional 360 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC boosted its stake in shares of Tempus AI by 6.7% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock valued at $525,000 after buying an additional 400 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Cantor Fitzgerald maintained its Buy rating, while HC Wainwright and Robert W. Baird were also reported to see strong potential appreciation. These recommendations may support investor confidence. Cantor Fitzgerald maintains Buy rating HC Wainwright forecast Baird forecast
• Positive Sentiment: Recent results were stronger than expected: Tempus reported quarterly revenue of $411.5 million, up 23.1% year over year, and earnings per share of $0.07 versus analysts’ forecast for a loss. The beat provides a favorable business-performance backdrop. Tempus AI earnings beat
• Negative Sentiment: CEO Ryan Fukushima sold 80 shares and director David Epstein sold 370 shares at $74.29. Both trades were executed under pre-arranged Rule 10b5-1 plans, and the small sales leave their substantial holdings largely intact, tempering the potential concern. Director stock sale disclosure

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.